Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,2600796,availability,"After HP administration, HPH appeared rapidly in plasma, but the HPH availability from HP amounted to only 17.8 +/- 3.7%, based on the comparison between the area under the plasma concentration curves of formed and iv HPH.","Pharmacokinetics and biotransformation of hydralazine acetone hydrazone, a metabolite of hydralazine, in the rat. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2600796/),%,17.8,23246,DB00119,Pyruvic acid
,2600796,fraction,"The fraction of HAH available to the systemic circulation as HPH was extremely low (7.8 +/- 2.2%), indicating that the conversion of HAH to HP was not so extensive.","Pharmacokinetics and biotransformation of hydralazine acetone hydrazone, a metabolite of hydralazine, in the rat. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2600796/),%,7.8,23247,DB00119,Pyruvic acid
,15464428,half-times,"DCA pharmacokinetics showed half-times approximately 86 min for the first intravenous dose of 50 mg/kg, 3.2 h for a subsequent intravenous dose 4-6 h later, and 11 h after continued oral dosing of 12.5-25 mg/kg twice daily.",Chronic treatment of mitochondrial disease patients with dichloroacetate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15464428/),min,86,43672,DB00119,Pyruvic acid
,15464428,half-times,"DCA pharmacokinetics showed half-times approximately 86 min for the first intravenous dose of 50 mg/kg, 3.2 h for a subsequent intravenous dose 4-6 h later, and 11 h after continued oral dosing of 12.5-25 mg/kg twice daily.",Chronic treatment of mitochondrial disease patients with dichloroacetate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15464428/),h,3.2,43673,DB00119,Pyruvic acid
,15464428,half-times,"DCA pharmacokinetics showed half-times approximately 86 min for the first intravenous dose of 50 mg/kg, 3.2 h for a subsequent intravenous dose 4-6 h later, and 11 h after continued oral dosing of 12.5-25 mg/kg twice daily.",Chronic treatment of mitochondrial disease patients with dichloroacetate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15464428/),h,11,43674,DB00119,Pyruvic acid
,20849350,relative bioavailability,"And the relative bioavailability of SEDDS for schisandrin and schisandrin B was 292.2% and 205.8% compared to the commercial capsules, respectively.",Enhanced oral bioavailability of Wurenchun (Fructus Schisandrae Chinensis extracts) by self-emulsifying drug delivery systems. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20849350/),%,292.2,59686,DB00119,Pyruvic acid
,20849350,relative bioavailability,"And the relative bioavailability of SEDDS for schisandrin and schisandrin B was 292.2% and 205.8% compared to the commercial capsules, respectively.",Enhanced oral bioavailability of Wurenchun (Fructus Schisandrae Chinensis extracts) by self-emulsifying drug delivery systems. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20849350/),%,205.8,59687,DB00119,Pyruvic acid
,515498,plasma half life,"The mean plasma half life of the pyruvic acid hydrazone was 156 min and mean urinary clearance, 28 ml/min.","Pharmacokinetics of hydralazine, apparent hydralazine and hydralazine pyruvic acid hydrazone in humans. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/515498/),min,156,107685,DB00119,Pyruvic acid
,515498,urinary clearance,"The mean plasma half life of the pyruvic acid hydrazone was 156 min and mean urinary clearance, 28 ml/min.","Pharmacokinetics of hydralazine, apparent hydralazine and hydralazine pyruvic acid hydrazone in humans. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/515498/),[ml] / [min],28,107686,DB00119,Pyruvic acid
,3692002,oral,"The single-dose oral LD50 values in Fischer 344 rats for technical-grade, 2,4-dichlorophenoxyacetic acid (2,4-D), esters, and salts ranged from 553 mg/kg (isobutyl ester in females) to 1090 mg/kg (dimethylamine salt in males).","Acute, pharmacokinetic, and subchronic toxicological studies of 2,4-dichlorophenoxyacetic acid. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3692002/),[mg] / [kg],553,113702,DB00119,Pyruvic acid
,3692002,LD50,"The single-dose oral LD50 values in Fischer 344 rats for technical-grade, 2,4-dichlorophenoxyacetic acid (2,4-D), esters, and salts ranged from 553 mg/kg (isobutyl ester in females) to 1090 mg/kg (dimethylamine salt in males).","Acute, pharmacokinetic, and subchronic toxicological studies of 2,4-dichlorophenoxyacetic acid. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3692002/),[mg] / [kg],553,113703,DB00119,Pyruvic acid
,3692002,LD50,"The single-dose oral LD50 values in Fischer 344 rats for technical-grade, 2,4-dichlorophenoxyacetic acid (2,4-D), esters, and salts ranged from 553 mg/kg (isobutyl ester in females) to 1090 mg/kg (dimethylamine salt in males).","Acute, pharmacokinetic, and subchronic toxicological studies of 2,4-dichlorophenoxyacetic acid. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3692002/),[mg] / [kg],1090,113704,DB00119,Pyruvic acid
greater,3692002,LD50,"Acute dermal LD50 values in rabbits for the acid, esters, and salts were greater than 2000 mg/kg.","Acute, pharmacokinetic, and subchronic toxicological studies of 2,4-dichlorophenoxyacetic acid. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3692002/),[mg] / [kg],2000,113705,DB00119,Pyruvic acid
less,3692002,no-observed-effect level (NOEL),"The no-observed-effect level (NOEL) was less than 15 mg/kg/day for both purified and technical-grade 2,4-D acid.","Acute, pharmacokinetic, and subchronic toxicological studies of 2,4-dichlorophenoxyacetic acid. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3692002/),[mg] / [d·kg],15,113706,DB00119,Pyruvic acid
,7787135,steady state (Css,"By using a loading dose of 300 mg kg-1, and an infusion rate of 7.5 mg min-1 kg-1 of PA, the concentration of PA reached a steady state (Css approximately equal to 100 micrograms mL-1) in 30 min.",The influence of pyruvic acid on the pharmacokinetics of sulphadiazine in rabbits. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7787135/),[μg] / [ml],100,133717,DB00119,Pyruvic acid
,7787135,beta half-life,"However, differences were found in the beta half-life, AUC, clearance, and k10 of SDZ in slow acetylators: the beta half-life decreased from 115.74 +/- 12.47 min to 62.96 +/- 4.36 min (p < 0.001); AUC decreased from 10,617.38 +/- 1179.81 micrograms min mL-1 to 6217.14 +/- 391.32 micrograms min mL-1 (p < 0.001); clearance increased from 0.0044 +/- 0.0008 L min-1 kg-1 to 0.0068 +/- 0.0007 L min-1 kg-1 (p < 0.001); and k10 increased from 0.0090 +/- 0.0009 min-1 to 0.0193 +/- 0.0028 min-1 (p < 0.005).",The influence of pyruvic acid on the pharmacokinetics of sulphadiazine in rabbits. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7787135/),min,115.74,133718,DB00119,Pyruvic acid
,7787135,beta half-life,"However, differences were found in the beta half-life, AUC, clearance, and k10 of SDZ in slow acetylators: the beta half-life decreased from 115.74 +/- 12.47 min to 62.96 +/- 4.36 min (p < 0.001); AUC decreased from 10,617.38 +/- 1179.81 micrograms min mL-1 to 6217.14 +/- 391.32 micrograms min mL-1 (p < 0.001); clearance increased from 0.0044 +/- 0.0008 L min-1 kg-1 to 0.0068 +/- 0.0007 L min-1 kg-1 (p < 0.001); and k10 increased from 0.0090 +/- 0.0009 min-1 to 0.0193 +/- 0.0028 min-1 (p < 0.005).",The influence of pyruvic acid on the pharmacokinetics of sulphadiazine in rabbits. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7787135/),min,62.96,133719,DB00119,Pyruvic acid
,7787135,AUC,"However, differences were found in the beta half-life, AUC, clearance, and k10 of SDZ in slow acetylators: the beta half-life decreased from 115.74 +/- 12.47 min to 62.96 +/- 4.36 min (p < 0.001); AUC decreased from 10,617.38 +/- 1179.81 micrograms min mL-1 to 6217.14 +/- 391.32 micrograms min mL-1 (p < 0.001); clearance increased from 0.0044 +/- 0.0008 L min-1 kg-1 to 0.0068 +/- 0.0007 L min-1 kg-1 (p < 0.001); and k10 increased from 0.0090 +/- 0.0009 min-1 to 0.0193 +/- 0.0028 min-1 (p < 0.005).",The influence of pyruvic acid on the pharmacokinetics of sulphadiazine in rabbits. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7787135/),[min·μg] / [ml],"10,617.38",133720,DB00119,Pyruvic acid
,7787135,AUC,"However, differences were found in the beta half-life, AUC, clearance, and k10 of SDZ in slow acetylators: the beta half-life decreased from 115.74 +/- 12.47 min to 62.96 +/- 4.36 min (p < 0.001); AUC decreased from 10,617.38 +/- 1179.81 micrograms min mL-1 to 6217.14 +/- 391.32 micrograms min mL-1 (p < 0.001); clearance increased from 0.0044 +/- 0.0008 L min-1 kg-1 to 0.0068 +/- 0.0007 L min-1 kg-1 (p < 0.001); and k10 increased from 0.0090 +/- 0.0009 min-1 to 0.0193 +/- 0.0028 min-1 (p < 0.005).",The influence of pyruvic acid on the pharmacokinetics of sulphadiazine in rabbits. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7787135/),[min·μg] / [ml],6217.14,133721,DB00119,Pyruvic acid
,7787135,clearance,"However, differences were found in the beta half-life, AUC, clearance, and k10 of SDZ in slow acetylators: the beta half-life decreased from 115.74 +/- 12.47 min to 62.96 +/- 4.36 min (p < 0.001); AUC decreased from 10,617.38 +/- 1179.81 micrograms min mL-1 to 6217.14 +/- 391.32 micrograms min mL-1 (p < 0.001); clearance increased from 0.0044 +/- 0.0008 L min-1 kg-1 to 0.0068 +/- 0.0007 L min-1 kg-1 (p < 0.001); and k10 increased from 0.0090 +/- 0.0009 min-1 to 0.0193 +/- 0.0028 min-1 (p < 0.005).",The influence of pyruvic acid on the pharmacokinetics of sulphadiazine in rabbits. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7787135/),[l] / [kg·min],0.0044,133722,DB00119,Pyruvic acid
,7787135,clearance,"However, differences were found in the beta half-life, AUC, clearance, and k10 of SDZ in slow acetylators: the beta half-life decreased from 115.74 +/- 12.47 min to 62.96 +/- 4.36 min (p < 0.001); AUC decreased from 10,617.38 +/- 1179.81 micrograms min mL-1 to 6217.14 +/- 391.32 micrograms min mL-1 (p < 0.001); clearance increased from 0.0044 +/- 0.0008 L min-1 kg-1 to 0.0068 +/- 0.0007 L min-1 kg-1 (p < 0.001); and k10 increased from 0.0090 +/- 0.0009 min-1 to 0.0193 +/- 0.0028 min-1 (p < 0.005).",The influence of pyruvic acid on the pharmacokinetics of sulphadiazine in rabbits. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7787135/),[l] / [kg·min],0.0068,133723,DB00119,Pyruvic acid
,7787135,k10,"However, differences were found in the beta half-life, AUC, clearance, and k10 of SDZ in slow acetylators: the beta half-life decreased from 115.74 +/- 12.47 min to 62.96 +/- 4.36 min (p < 0.001); AUC decreased from 10,617.38 +/- 1179.81 micrograms min mL-1 to 6217.14 +/- 391.32 micrograms min mL-1 (p < 0.001); clearance increased from 0.0044 +/- 0.0008 L min-1 kg-1 to 0.0068 +/- 0.0007 L min-1 kg-1 (p < 0.001); and k10 increased from 0.0090 +/- 0.0009 min-1 to 0.0193 +/- 0.0028 min-1 (p < 0.005).",The influence of pyruvic acid on the pharmacokinetics of sulphadiazine in rabbits. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7787135/),1/[min],0.0090,133724,DB00119,Pyruvic acid
,7787135,k10,"However, differences were found in the beta half-life, AUC, clearance, and k10 of SDZ in slow acetylators: the beta half-life decreased from 115.74 +/- 12.47 min to 62.96 +/- 4.36 min (p < 0.001); AUC decreased from 10,617.38 +/- 1179.81 micrograms min mL-1 to 6217.14 +/- 391.32 micrograms min mL-1 (p < 0.001); clearance increased from 0.0044 +/- 0.0008 L min-1 kg-1 to 0.0068 +/- 0.0007 L min-1 kg-1 (p < 0.001); and k10 increased from 0.0090 +/- 0.0009 min-1 to 0.0193 +/- 0.0028 min-1 (p < 0.005).",The influence of pyruvic acid on the pharmacokinetics of sulphadiazine in rabbits. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7787135/),1/[min],0.0193,133725,DB00119,Pyruvic acid
,19780144,permeability,"The Caco-2 permeability, tested at 200 microM, was quantitatively predictive of in vivo oral absorption, with complete absorption occurring at a Caco-2 permeability of 100 nm/s or higher.","Utilization of in vitro Caco-2 permeability and liver microsomal half-life screens in discovering BMS-488043, a novel HIV-1 attachment inhibitor with improved pharmacokinetic properties. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19780144/),[nm] / [s],100,134995,DB00119,Pyruvic acid
,19780144,permeability,"Among the >100 compounds evaluated, BMS-488043 emerged as a lead, exhibiting a Caco-2 permeability of 178 nm/s and a microsomal half-life predictive of a low clearance (4 mL/min/kg) in humans.","Utilization of in vitro Caco-2 permeability and liver microsomal half-life screens in discovering BMS-488043, a novel HIV-1 attachment inhibitor with improved pharmacokinetic properties. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19780144/),[nm] / [s],178,134996,DB00119,Pyruvic acid
,19780144,clearance,"Among the >100 compounds evaluated, BMS-488043 emerged as a lead, exhibiting a Caco-2 permeability of 178 nm/s and a microsomal half-life predictive of a low clearance (4 mL/min/kg) in humans.","Utilization of in vitro Caco-2 permeability and liver microsomal half-life screens in discovering BMS-488043, a novel HIV-1 attachment inhibitor with improved pharmacokinetic properties. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19780144/),[ml] / [kg·min],4,134997,DB00119,Pyruvic acid
,19780144,oral bioavailability,"The oral bioavailability of BMS-488043 in rats, dogs, and monkeys was 90%, 57%, and 60%, respectively.","Utilization of in vitro Caco-2 permeability and liver microsomal half-life screens in discovering BMS-488043, a novel HIV-1 attachment inhibitor with improved pharmacokinetic properties. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19780144/),%,90,134998,DB00119,Pyruvic acid
,19780144,oral bioavailability,"The oral bioavailability of BMS-488043 in rats, dogs, and monkeys was 90%, 57%, and 60%, respectively.","Utilization of in vitro Caco-2 permeability and liver microsomal half-life screens in discovering BMS-488043, a novel HIV-1 attachment inhibitor with improved pharmacokinetic properties. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19780144/),%,57,134999,DB00119,Pyruvic acid
,19780144,oral bioavailability,"The oral bioavailability of BMS-488043 in rats, dogs, and monkeys was 90%, 57%, and 60%, respectively.","Utilization of in vitro Caco-2 permeability and liver microsomal half-life screens in discovering BMS-488043, a novel HIV-1 attachment inhibitor with improved pharmacokinetic properties. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19780144/),%,60,135000,DB00119,Pyruvic acid
,19780144,terminal half-life,"The clearance was low in all three species tested, with a terminal half-life ranging from 2.4 to 4.7 h.","Utilization of in vitro Caco-2 permeability and liver microsomal half-life screens in discovering BMS-488043, a novel HIV-1 attachment inhibitor with improved pharmacokinetic properties. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19780144/),h,2.4 to 4.7,135001,DB00119,Pyruvic acid
,19780144,permeability,"Furthermore, the oral exposure of BMS-488043 was significantly improved (6- to 12-fold in rats and monkeys) compared to the prototype compound BMS-378806 that had a suboptimal Caco-2 permeability (51 nm/s) and microsomal half-life.","Utilization of in vitro Caco-2 permeability and liver microsomal half-life screens in discovering BMS-488043, a novel HIV-1 attachment inhibitor with improved pharmacokinetic properties. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19780144/),[nm] / [s],51,135002,DB00119,Pyruvic acid
,24662525,Area under curve (AUC),Area under curve (AUC) of IMI ranged from 35 to 358μg/ml/h; 6-CNA: 27.12-1006.42μg/ml/h and 6-HNA: 14.98-302.74μg/ml/h in different organs and bodily fluids.,Disposition and acute toxicity of imidacloprid in female rats after single exposure. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24662525/),[μg] / [h·ml],35 to 358,137097,DB00119,Pyruvic acid
,24662525,Area under curve (AUC),Area under curve (AUC) of IMI ranged from 35 to 358μg/ml/h; 6-CNA: 27.12-1006.42μg/ml/h and 6-HNA: 14.98-302.74μg/ml/h in different organs and bodily fluids.,Disposition and acute toxicity of imidacloprid in female rats after single exposure. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24662525/),[μg] / [h·ml],27.12-1006.42,137098,DB00119,Pyruvic acid
,24662525,Area under curve (AUC),Area under curve (AUC) of IMI ranged from 35 to 358μg/ml/h; 6-CNA: 27.12-1006.42μg/ml/h and 6-HNA: 14.98-302.74μg/ml/h in different organs and bodily fluids.,Disposition and acute toxicity of imidacloprid in female rats after single exposure. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24662525/),[μg] / [h·ml],14.98-302.74,137099,DB00119,Pyruvic acid
,6177931,potency ratio,"Both compounds caused a dose-dependent depressor response, with a potency ratio of HAH to H of approximately 0.2.",Hypotensive effect of the hydralazine--acetone hydrazone in conscious rabbits: evidence for its back-conversion to hydralazine in vivo. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6177931/),,0.2,162134,DB00119,Pyruvic acid
,9591306,urinary excretion,"The average 24-h urinary excretion of C12 was 6.5% versus 6.7% of the administered dose, respectively, in NIDDM patients and in healthy controls.",The metabolic effect of dodecanedioic acid infusion in non-insulin-dependent diabetic patients. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9591306/),%,6.5,165730,DB00119,Pyruvic acid
,9591306,urinary excretion,"The average 24-h urinary excretion of C12 was 6.5% versus 6.7% of the administered dose, respectively, in NIDDM patients and in healthy controls.",The metabolic effect of dodecanedioic acid infusion in non-insulin-dependent diabetic patients. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9591306/),%,6.7,165731,DB00119,Pyruvic acid
,9591306,area under the curve (AUC),The area under the curve (AUC) values of plasma C12 were 279.9 +/- 42.7 mumol in NIDDM patients and 219.7 +/- 14.0 mumol in controls (P = ns).,The metabolic effect of dodecanedioic acid infusion in non-insulin-dependent diabetic patients. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9591306/),μM,279.9,165732,DB00119,Pyruvic acid
,9591306,area under the curve (AUC),The area under the curve (AUC) values of plasma C12 were 279.9 +/- 42.7 mumol in NIDDM patients and 219.7 +/- 14.0 mumol in controls (P = ns).,The metabolic effect of dodecanedioic acid infusion in non-insulin-dependent diabetic patients. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9591306/),μM,219.7,165733,DB00119,Pyruvic acid
,9591306,Lactate plasma concentration,"Lactate plasma concentration decreased in NIDDM patients from 3.5 +/- 0.2 to 1.5 +/- 0.1 mM (P < 0.001), whereas blood pyruvate increased at the end of the experimental session from 26.0 +/- 11.6 to 99.5 +/- 14.9 microM (P < 0.01).",The metabolic effect of dodecanedioic acid infusion in non-insulin-dependent diabetic patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9591306/),mM,3.5,165734,DB00119,Pyruvic acid
,9591306,Lactate plasma concentration,"Lactate plasma concentration decreased in NIDDM patients from 3.5 +/- 0.2 to 1.5 +/- 0.1 mM (P < 0.001), whereas blood pyruvate increased at the end of the experimental session from 26.0 +/- 11.6 to 99.5 +/- 14.9 microM (P < 0.01).",The metabolic effect of dodecanedioic acid infusion in non-insulin-dependent diabetic patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9591306/),mM,1.5,165735,DB00119,Pyruvic acid
,1673428,Hepatic extraction,Hepatic extraction of POH averaged 0.49 and that of PO was nearly complete at 0.96.,Prednisolone and prednisone exhibit linear extraction in the perfused rabbit liver. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1673428/),,0.49,171380,DB00119,Pyruvic acid
,1673428,Hepatic extraction,Hepatic extraction of POH averaged 0.49 and that of PO was nearly complete at 0.96.,Prednisolone and prednisone exhibit linear extraction in the perfused rabbit liver. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1673428/),,0,171381,DB00119,Pyruvic acid
,1673428,apparent hepatic blood clearance,"The apparent hepatic blood clearance of POH was about 16 ml/min and that of PO approximated liver blood flow, at 30 ml/min.",Prednisolone and prednisone exhibit linear extraction in the perfused rabbit liver. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1673428/),[ml] / [min],16,171382,DB00119,Pyruvic acid
,1673428,apparent hepatic blood clearance,"The apparent hepatic blood clearance of POH was about 16 ml/min and that of PO approximated liver blood flow, at 30 ml/min.",Prednisolone and prednisone exhibit linear extraction in the perfused rabbit liver. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1673428/),[ml] / [min],30,171383,DB00119,Pyruvic acid
,7438695,bioavailability,"Hydralazine bioavailability in the fast acetylator group (9.5% single dose, 6.6% repeated doses) and in the slow acetylator group (31.3% single dose, 39.3% repeated doses) was phenotype dependent.",Hydralazine kinetics after single and repeated oral doses. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7438695/),%,9.5,190285,DB00119,Pyruvic acid
,7438695,bioavailability,"Hydralazine bioavailability in the fast acetylator group (9.5% single dose, 6.6% repeated doses) and in the slow acetylator group (31.3% single dose, 39.3% repeated doses) was phenotype dependent.",Hydralazine kinetics after single and repeated oral doses. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7438695/),%,6.6,190286,DB00119,Pyruvic acid
,7438695,bioavailability,"Hydralazine bioavailability in the fast acetylator group (9.5% single dose, 6.6% repeated doses) and in the slow acetylator group (31.3% single dose, 39.3% repeated doses) was phenotype dependent.",Hydralazine kinetics after single and repeated oral doses. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7438695/),%,31.3,190287,DB00119,Pyruvic acid
,7438695,bioavailability,"Hydralazine bioavailability in the fast acetylator group (9.5% single dose, 6.6% repeated doses) and in the slow acetylator group (31.3% single dose, 39.3% repeated doses) was phenotype dependent.",Hydralazine kinetics after single and repeated oral doses. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7438695/),%,39.3,190288,DB00119,Pyruvic acid
,7438695,Peak plasma levels,Peak plasma levels were lower than those reported with nonspecific assays: 0.32 microM for the single dose and 0.14 microM for repeated doses in the fast acetylator group and 1.03 microM for the single dose and 0.96 microM repeated doses in the slow acetylator group.,Hydralazine kinetics after single and repeated oral doses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7438695/),μM,0.32,190289,DB00119,Pyruvic acid
,7438695,Peak plasma levels,Peak plasma levels were lower than those reported with nonspecific assays: 0.32 microM for the single dose and 0.14 microM for repeated doses in the fast acetylator group and 1.03 microM for the single dose and 0.96 microM repeated doses in the slow acetylator group.,Hydralazine kinetics after single and repeated oral doses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7438695/),μM,0.14,190290,DB00119,Pyruvic acid
,7438695,Peak plasma levels,Peak plasma levels were lower than those reported with nonspecific assays: 0.32 microM for the single dose and 0.14 microM for repeated doses in the fast acetylator group and 1.03 microM for the single dose and 0.96 microM repeated doses in the slow acetylator group.,Hydralazine kinetics after single and repeated oral doses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7438695/),μM,1.03,190291,DB00119,Pyruvic acid
,7438695,Peak plasma levels,Peak plasma levels were lower than those reported with nonspecific assays: 0.32 microM for the single dose and 0.14 microM for repeated doses in the fast acetylator group and 1.03 microM for the single dose and 0.96 microM repeated doses in the slow acetylator group.,Hydralazine kinetics after single and repeated oral doses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7438695/),μM,0.96,190292,DB00119,Pyruvic acid
,7438695,Elimination half-lifes,"Elimination half-lifes were phenotype independent, ranging from 4 to 6 hr.",Hydralazine kinetics after single and repeated oral doses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7438695/),h,4 to 6,190293,DB00119,Pyruvic acid
,10780953,VO(2 max),"Seven fit male subjects (26 +/- 2 yr, body mass index 23 +/- 0.5 kg/m(2), VO(2 max) 65 +/- 5 ml x kg(-1) x min(-1)) underwent 40 min of postabsorptive cycle ergometer exercise (145 +/- 14 W) once without [control (CON)] and once with Epi infusion [EPI (0.1 microg x kg(-1) x min(-1))] from 30 to 40 min.",Epinephrine infusion during moderate intensity exercise increases glucose production and uptake. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10780953/),[ml] / [kg·min],65,221477,DB00119,Pyruvic acid
,10780953,Epi levels,"Epi levels reached 9.4 +/- 0.8 nM (20x rest, 10x CON).",Epinephrine infusion during moderate intensity exercise increases glucose production and uptake. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10780953/),nM,9.4,221478,DB00119,Pyruvic acid
,10780953,R(a),R(a) increased approximately 70% to 3.75 +/- 0.53 in CON but to 8.57 +/- 0.58 mg x kg(-1) x min(-1) in EPI (P < 0.001).,Epinephrine infusion during moderate intensity exercise increases glucose production and uptake. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10780953/),[mg] / [kg·min],3.75,221479,DB00119,Pyruvic acid
,10780953,R(a),R(a) increased approximately 70% to 3.75 +/- 0.53 in CON but to 8.57 +/- 0.58 mg x kg(-1) x min(-1) in EPI (P < 0.001).,Epinephrine infusion during moderate intensity exercise increases glucose production and uptake. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10780953/),[mg] / [kg·min],8.57,221480,DB00119,Pyruvic acid
,10780953,peak R(d),"In EPI, peak R(d) (5.55 +/- 0.54 vs.",Epinephrine infusion during moderate intensity exercise increases glucose production and uptake. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10780953/),,5.55,221481,DB00119,Pyruvic acid
,10780953,R(a)-to-R(d),"The R(a)-to-R(d) imbalance in EPI caused hyperglycemia (7.12 +/- 0.22 vs. 5.59 +/- 0.22 mM, P = 0.001) until minute 60 of recovery.",Epinephrine infusion during moderate intensity exercise increases glucose production and uptake. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10780953/),,7,221482,DB00119,Pyruvic acid
,10780953,R(a)-to-R(d),"The R(a)-to-R(d) imbalance in EPI caused hyperglycemia (7.12 +/- 0.22 vs. 5.59 +/- 0.22 mM, P = 0.001) until minute 60 of recovery.",Epinephrine infusion during moderate intensity exercise increases glucose production and uptake. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10780953/),,5,221483,DB00119,Pyruvic acid
,19100319,solubility,BMS-488043 is classified as a Biopharmaceutics Classification System (BCS) Class-II compound with a poor aqueous solubility of 0.04mg/mL and an acceptable permeability of 178nm/s in the Caco2 cell-line model.,Enhancement of oral bioavailability of an HIV-attachment inhibitor by nanosizing and amorphous formulation approaches. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19100319/),[mg] / [ml],0.04,223683,DB00119,Pyruvic acid
,19100319,permeability,BMS-488043 is classified as a Biopharmaceutics Classification System (BCS) Class-II compound with a poor aqueous solubility of 0.04mg/mL and an acceptable permeability of 178nm/s in the Caco2 cell-line model.,Enhancement of oral bioavailability of an HIV-attachment inhibitor by nanosizing and amorphous formulation approaches. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19100319/),[nm] / [s],178,223684,DB00119,Pyruvic acid
,8135655,invasion constants,"Oral doses of 1 and 5 ml/kg 14C-diethylene glycol (DEG) given to rats were rapidly and almost completely absorbed, the invasion constants being 2.95 h-1 and 4.24 h-1.",Toxicokinetics of diethylene glycol (DEG) in the rat. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8135655/),1/[h],2.95,232422,DB00119,Pyruvic acid
,8135655,invasion constants,"Oral doses of 1 and 5 ml/kg 14C-diethylene glycol (DEG) given to rats were rapidly and almost completely absorbed, the invasion constants being 2.95 h-1 and 4.24 h-1.",Toxicokinetics of diethylene glycol (DEG) in the rat. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8135655/),1/[h],4.24,232423,DB00119,Pyruvic acid
,8135655,VD,"VD, was determined at 298 ml, indicating distribution over the whole body.",Toxicokinetics of diethylene glycol (DEG) in the rat. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8135655/),ml,298,232424,DB00119,Pyruvic acid
,8135655,half-life,"After oral doses of 1, 5, and 10 ml 14C-DEG/kg 64, 87, and 91% of 14C activity in rat blood disappeared in 12-16 h with a half-life of 3.4 h and the remaining 9, 5, and 4% with half-lives of 39 h, 45 h, and 49 h.",Toxicokinetics of diethylene glycol (DEG) in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8135655/),h,3.4,232425,DB00119,Pyruvic acid
,8135655,half-lives,"After oral doses of 1, 5, and 10 ml 14C-DEG/kg 64, 87, and 91% of 14C activity in rat blood disappeared in 12-16 h with a half-life of 3.4 h and the remaining 9, 5, and 4% with half-lives of 39 h, 45 h, and 49 h.",Toxicokinetics of diethylene glycol (DEG) in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8135655/),h,39,232426,DB00119,Pyruvic acid
,8135655,half-lives,"After oral doses of 1, 5, and 10 ml 14C-DEG/kg 64, 87, and 91% of 14C activity in rat blood disappeared in 12-16 h with a half-life of 3.4 h and the remaining 9, 5, and 4% with half-lives of 39 h, 45 h, and 49 h.",Toxicokinetics of diethylene glycol (DEG) in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8135655/),h,45,232427,DB00119,Pyruvic acid
,8135655,half-lives,"After oral doses of 1, 5, and 10 ml 14C-DEG/kg 64, 87, and 91% of 14C activity in rat blood disappeared in 12-16 h with a half-life of 3.4 h and the remaining 9, 5, and 4% with half-lives of 39 h, 45 h, and 49 h.",Toxicokinetics of diethylene glycol (DEG) in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8135655/),h,49,232428,DB00119,Pyruvic acid
,8135655,half-lives,From the cumulative urinary excretion kinetics half-lives of 6 h were determined for doses of 1 and 5 ml/kg and 10 h for the dose of 10 ml/kg.,Toxicokinetics of diethylene glycol (DEG) in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8135655/),h,6,232429,DB00119,Pyruvic acid
,8135655,half-lives,From the cumulative urinary excretion kinetics half-lives of 6 h were determined for doses of 1 and 5 ml/kg and 10 h for the dose of 10 ml/kg.,Toxicokinetics of diethylene glycol (DEG) in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8135655/),h,10,232430,DB00119,Pyruvic acid
,8135655,elimination half-lives,Thereafter urinary excretion followed first order kinetics with elimination half-lives of 3.6 h.,Toxicokinetics of diethylene glycol (DEG) in the rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8135655/),h,3.6,232431,DB00119,Pyruvic acid
,8135655,VD,"VD of 297 ml, the total clearance of 14C activity was determined at 63 ml/h, and the renal clearance of unmetabolized DEG was 66 ml/h.",Toxicokinetics of diethylene glycol (DEG) in the rat. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8135655/),ml,297,232432,DB00119,Pyruvic acid
,8135655,total clearance of 14C activity,"VD of 297 ml, the total clearance of 14C activity was determined at 63 ml/h, and the renal clearance of unmetabolized DEG was 66 ml/h.",Toxicokinetics of diethylene glycol (DEG) in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8135655/),[ml] / [h],63,232433,DB00119,Pyruvic acid
,8135655,renal clearance,"VD of 297 ml, the total clearance of 14C activity was determined at 63 ml/h, and the renal clearance of unmetabolized DEG was 66 ml/h.",Toxicokinetics of diethylene glycol (DEG) in the rat. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8135655/),[ml] / [h],66,232434,DB00119,Pyruvic acid
,8135655,ratio of ClDEG to Cl,The ratio of ClDEG to Cl(inulin) = 0.64 indicated that DEG and its metabolite 2-hydroxyethoxyacetate (2-HEAA) were reabsorbed from the tubuli into the blood capillaries.,Toxicokinetics of diethylene glycol (DEG) in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8135655/),,0.64,232435,DB00119,Pyruvic acid
,7438689,"Total plasma clearance, CLT","Total plasma clearance, CLT[72.9 +/- 4.9 (SEM) ml . min-1 . kg-1], apparent volume of distribution, Vd area (5.83 +/- 0.30 1 . kg-1), steady-state volume of distribution, Vd ss (1.83 +/- 0.17 . kg-1), and terminal half-life, t1/2 (53.7 min, harmonic mean) were independent of acetylator phenotype.",Hydralazine kinetics in hypertensive patients after intravenous administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7438689/),[ml] / [kg·min],72.9,232889,DB00119,Pyruvic acid
,7438689,"apparent volume of distribution, Vd area","Total plasma clearance, CLT[72.9 +/- 4.9 (SEM) ml . min-1 . kg-1], apparent volume of distribution, Vd area (5.83 +/- 0.30 1 . kg-1), steady-state volume of distribution, Vd ss (1.83 +/- 0.17 . kg-1), and terminal half-life, t1/2 (53.7 min, harmonic mean) were independent of acetylator phenotype.",Hydralazine kinetics in hypertensive patients after intravenous administration. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7438689/),[1] / [kg],5.83,232890,DB00119,Pyruvic acid
,7438689,"steady-state volume of distribution, Vd ss","Total plasma clearance, CLT[72.9 +/- 4.9 (SEM) ml . min-1 . kg-1], apparent volume of distribution, Vd area (5.83 +/- 0.30 1 . kg-1), steady-state volume of distribution, Vd ss (1.83 +/- 0.17 . kg-1), and terminal half-life, t1/2 (53.7 min, harmonic mean) were independent of acetylator phenotype.",Hydralazine kinetics in hypertensive patients after intravenous administration. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7438689/),1/[kg],1.83,232891,DB00119,Pyruvic acid
,7438689,"terminal half-life, t1/2","Total plasma clearance, CLT[72.9 +/- 4.9 (SEM) ml . min-1 . kg-1], apparent volume of distribution, Vd area (5.83 +/- 0.30 1 . kg-1), steady-state volume of distribution, Vd ss (1.83 +/- 0.17 . kg-1), and terminal half-life, t1/2 (53.7 min, harmonic mean) were independent of acetylator phenotype.",Hydralazine kinetics in hypertensive patients after intravenous administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7438689/),min,53.7,232892,DB00119,Pyruvic acid
,7438689,t1/2,Peak HPH concentrations occurred 10 to 60 min after dose; mean HPH t1/2 was 239 min.,Hydralazine kinetics in hypertensive patients after intravenous administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7438689/),min,239,232893,DB00119,Pyruvic acid
,7438689,t1/2,"""Apparent"" hydralazine concentrations were usually highest in the 2-min plasma sample and declined with a mean t1/2 of 296 min.",Hydralazine kinetics in hypertensive patients after intravenous administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7438689/),min,296,232894,DB00119,Pyruvic acid
below,29090487,peak signal-to-noise ratio,The reproducibility of kPL estimates worsened quickly when peak signal-to-noise ratio for hyperpolarized pyruvate was below approximately 20.,Influence of parameter accuracy on pharmacokinetic analysis of hyperpolarized pyruvate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29090487/),,20,256175,DB00119,Pyruvic acid
above,29090487,peak signal-to-noise ratio,The accuracy and precision of kPL estimates improve substantially for peak signal-to-noise ratio above approximately 20.,Influence of parameter accuracy on pharmacokinetic analysis of hyperpolarized pyruvate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29090487/),,20,256176,DB00119,Pyruvic acid
